DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
29 hedge funds and large institutions have $9.8M invested in DMK Pharmaceuticals Corporation Common Stock in 2015 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
38% more funds holding
Funds holding: 21 → 29 (+8)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less capital invested
Capital invested by funds: $11.8M → $9.8M (-$2M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $16K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.71M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.09M |
| 3 |
PVI
Pura Vida Investments
New York
|
+$497K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$320K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$285K |
| 2 |
Goldman Sachs
New York
|
-$264K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$161K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$99K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$15.5K |
DMK Hedge Fund Activity: Q1 2015 in Review
29 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2015, worth a combined $9.8M — down 17% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DMK positions and 2 closed out — a net gain of 8 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Marshall Wace, adding an estimated $1.71M. The largest seller was BlackRock Institutional Trust, cutting an estimated $285K.
- 29 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2015, up from 21 in Q4 2014.
- Funds reported $9.8M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2015, down 17% quarter-over-quarter.
- 10 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2015 and 2 closed out, a net change of +8 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2015 was Marshall Wace, an estimated $1.71M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2015 was BlackRock Institutional Trust, an estimated $285K sold.
Based on aggregated 13F filings for Q1 2015.